1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Biofrontera AG
  6. News
  7. Summary
    B8F   DE0006046113

BIOFRONTERA AG

(B8F)
  Report
Delayed Xetra  -  05/27 11:36:12 am EDT
1.125 EUR   +0.90%
05/19TRANSCRIPT : Biofrontera AG, Q1 2022 Earnings Call, May 19, 2022
CI
05/17Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/13Earnings Flash (BFRI) BIOFRONTERA Posts Q1 Revenue $9.8M, vs. Street Est of $9.83M
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

European ADRs Move Higher in Monday Trading

12/27/2021 | 11:50am EDT


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
ADAPTIMMUNE THERAPEUTICS PLC 4.11% 1.52 Delayed Quote.-59.47%
AMARIN CORPORATION PLC 0.70% 1.44 Delayed Quote.-57.27%
AUTOLUS THERAPEUTICS PLC 1.55% 2.62 Delayed Quote.-49.52%
AVADEL PHARMACEUTICALS PLC 133.64% 2.5 Delayed Quote.-69.06%
BIOFRONTERA AG 0.90% 1.125 Delayed Quote.-23.99%
EDAP TMS S.A. -0.56% 7.1 Delayed Quote.18.53%
ENDAVA PLC 14.28% 105.02 Delayed Quote.-37.46%
GENFIT 2.15% 3.32 Real-time Quote.-23.08%
MEREO BIOPHARMA GROUP PLC 8.77% 0.521 Delayed Quote.-67.44%
NATUZZI S.P.A. 8.57% 10.39 Delayed Quote.-34.78%
VEON LTD. 6.12% 0.52 Delayed Quote.-69.59%
VERONA PHARMA PLC 0.45% 4.48 Delayed Quote.-33.33%
VOXELJET AG 2.93% 4.045 Delayed Quote.-31.44%
ZEALAND PHARMA A/S 1.98% 92.5 Delayed Quote.-36.25%
All news about BIOFRONTERA AG
05/19TRANSCRIPT : Biofrontera AG, Q1 2022 Earnings Call, May 19, 2022
CI
05/17Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/13Earnings Flash (BFRI) BIOFRONTERA Posts Q1 Revenue $9.8M, vs. Street Est of $9.83M
MT
05/02TRANSCRIPT : Biofrontera AG, 2021 Earnings Call, May 02, 2022
CI
04/30Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2021
CI
04/30PTA-NEWS : Biofrontera AG: Biofrontera reports results for the fiscal year 2021
PU
04/29Biofrontera AG Provides Earnings Guidance for the Year 2022
CI
04/28PTA-NEWS : Biofrontera AG: Biofrontera shifts the publication of the Annual Report 2021 to..
PU
04/14PTA-NEWS : Biofrontera AG: Biofrontera announces conference call to be held on April 29, 2..
PU
04/13Top Midday Gainers
MT
More news
Financials
Sales 2022 35,7 M 38,2 M 38,2 M
Net income 2022 -29,0 M -31,1 M -31,1 M
Net Debt 2022 - - -
P/E ratio 2022 -2,50x
Yield 2022 -
Capitalization 63,8 M 68,4 M 68,4 M
Capi. / Sales 2022 1,79x
Capi. / Sales 2023 1,83x
Nbr of Employees 95
Free-Float 46,4%
Chart BIOFRONTERA AG
Duration : Period :
Biofrontera AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOFRONTERA AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,13 €
Average target price 3,35 €
Spread / Average Target 198%
EPS Revisions
Managers and Directors
Ludwig Lutter Chief Financial Officer
Wilhelm Konrad Zours Chairman-Supervisory Board
Heikki Lanckriet Member-Supervisory Board
Helge Lubenow Member-Supervisory Board
Karlheinz Schmelig Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BIOFRONTERA AG-23.99%68
CSL LIMITED-7.46%92 708
SAMSUNG BIOLOGICS CO.,LTD.-7.64%47 463
BIOGEN INC.-14.05%30 198
WUXI BIOLOGICS (CAYMAN) INC.-41.33%29 183
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-32.02%20 229